Articles tagged with Thrombosis
Cleveland researchers reveal a new strategy to prevent blood clots by targeting overactive neutrophils, reducing clotting risk while minimizing bleeding risk. The findings may be especially impactful for cancer patients who experience blood clot complications.
A Johns Hopkins Medicine study found that patient education and nurse performance feedback can significantly reduce missed or refused doses of VTE-preventing drugs. The interventions resulted in a 36% drop in missed doses, with the patient education bundle showing a 44% reduction.
A clinical trial has shown that full-dose anticoagulation therapy is more effective than standard-dose prophylactic anticoagulation in preventing blood clotting complications in COVID-19 patients. The study found a significant reduction in venous or arterial clotting complications among patients who received full-dose treatment.
A new study by Marshall University researchers found that inhibiting Na+/K+ ATPase alpha 1 subunit proteins dramatically inhibited in vivo thrombosis in male mice. The study suggests that targeting this protein could lead to a novel anti-thrombotic therapy with fewer side effects.
Researchers found that a thymidine phosphorylase (TYMP) inhibitor could help slow thrombosis in COVID-19 patients by targeting the SARS-CoV-2 spike protein. The gene's increased expression is linked to D-dimer levels and COVID-19 severity.
Researchers found clots in small venous and arterial blood vessels in normal-looking skin from patients with severe COVID-19, distinguishable from other forms of respiratory illness. Antiviral proteins and interferon-induced inflammatory proteins were also detected, associated with disease severity.
Researchers found that patients with isolated distal DVT had lower co-morbidity burden, lower risk of mortality, and fewer pulmonary embolism cases compared to those with proximal DVT. Despite less severe outcomes, these patients were still at risk for developing post-thrombotic syndrome after treatment.
A study found that around one in 500 men carry an extra sex chromosome, putting them at increased risk of several common diseases. Men with XXY or XYY chromosomes have higher risks of reproductive problems, type 2 diabetes, and other health conditions.
Researchers found that inhibiting caspase 11 reduced inflammation, tissue injury and blood clots in lung tissue of infected mice. This suggests potential therapeutic targets for treating severe COVID-19 symptoms.
Patients with a history of unprovoked venous thromboembolism who stop treatment after negative D-dimer tests experience an eight-fold increased risk of recurrence compared to those on low-dose apixaban. Low-dose apixaban was found safe and effective for these patients
A real-world study found that clopidogrel monotherapy was associated with reduced risk of net adverse clinical events and major cardiac events, compared to aspirin monotherapy. Clopidogrel also showed a lower incidence rate of clinically relevant bleeding events.
A research team discovered that an excessive number of thromboxane A2 receptors in blood vessel cells hinders the formation of new blood vessels, leading to vascular and cardiovascular diseases. The finding offers a promising biomarker for treatment and potential therapeutic benefits from blocking the receptor's action.
Researchers discovered a connection between atherosclerotic plaques and the central nervous system, involving immune cells, nerves, and cardiovascular tissues. This 'ABC' circuit can be modulated or disconnected, potentially leading to innovative therapies for treating atherosclerosis.
Researchers have identified a new signaling pathway of blood clotting and demonstrated how it can be experimentally inhibited to reduce the risk of thrombosis. By targeting platelet-derived CXCL12, the approach may offer additional benefits without increasing the risk of bleeding.
Researchers discovered a link between non-O blood types and an increased risk of developing venous thromboembolism in cancer patients. This finding suggests that blood typing may serve as another important predictive measure for identifying individuals at high risk.
A new study shows that the telestroke program prevents unnecessary hospital transfers for stroke patients, decreasing rural healthcare disparities. The program increases care efficiency and cost-effectiveness, while optimizing care for patients.
A post-hoc subgroup analysis of the AFIRE trial found that reduced kidney function significantly influences bleeding events during antithrombotic therapy. Patients with healthy kidney function have a decreased risk of bleeding over time, while those with reduced kidney function remain at high risk.
Researchers identified common features of pediatric antiphospholipid syndrome, a rare autoimmune disease causing inflammation and recurring blood clots. Nearly half of children with APS experienced recurrent blood clots despite treatment, highlighting the need for early diagnosis and prevention.
Two studies found a slight increase in the risk of intracranial thrombosis events following AstraZeneca vaccination. The risks were higher in people under 70 years old, with an estimated excess risk of 0.9–3 per million.
Researchers found higher-than-expected levels of antiphospholipid autoantibodies in COVID-19 patients, causing endothelial cell activation and promoting clotting. Removing these antibodies from blood samples lost the activation effect, suggesting a potential cause of severe COVID-19 symptoms.
Researchers compared two treatment methods for wide-neck aneurysms: microsurgery with clips and coils/stents deployed via catheters. Microsurgery was found to be longer-lasting, but endovascular therapy showed superior clinical outcomes in unruptured aneurysms.
Researchers discovered that activation of two specific receptors on platelets leads to cerebral venous thrombosis. The receptors CLEC-2 and GPIIb/IIIa are involved in the development of the disease, which affects younger people more often than classic strokes.
A new study published in Mayo Clinic Proceedings found that direct oral anticoagulants significantly decrease cancer-associated venous thrombosis recurrence without increasing bleeding. The study involved 2,894 patients and showed a 41% decrease in thrombosis recurrence with direct oral anticoagulants compared to parenteral dalteparin.
A new study from Brigham and Women's Hospital identified the activation of PIEZO1 as a key trigger for thrombosis in patients with type 2 diabetes. Inhibiting PIEZO1 prevented clot formation, suggesting its potential as a therapeutic target for preventing thrombosis.
Researchers at the University of Tokyo and University of Virginia developed a new diagnostic technology that can identify patients at risk of microvascular thrombosis. The technology analyzes blood samples to detect excessive platelet aggregation, an early indicator of blood clotting, in nearly 90% of COVID-19 patients.
Recent research reveals that endothelial cells produce all necessary coagulation proteins for thrombin generation, enabling the clotting process to occur on their surfaces. This finding shifts our understanding of blood clot development and treatment strategies.
A study examining autopsy tissue samples from COVID-19 patients found frequent and extensive blood clots within heart vessels, but no typical endothelial cell changes. Instead, hypercoagulability of the blood caused by activated neutrophils was detected as a likely culprit.
A modeling study found that annual mammography screening beyond age 75 may provide little to no benefit in terms of lives saved, while increasing costs and potential harms from overdiagnosis. Biennial screening up to age 80 is more cost-effective but yields a small number of deaths averted.
A study analyzing data from 109 COVID-19 patients found that obesity is the key factor associated with endothelial dysfunction, a condition increasing heart attack and stroke risk. The results suggest an 17% higher cardiovascular risk for obese patients compared to those of normal weight.
A recent study published in JAMA Internal Medicine investigated the incidence of cerebral venous sinus thrombosis (CVST) after post-vaccination. The researchers found that the rate of this rare adverse effect is significantly higher than pre-pandemic rates, prompting consideration of vaccine effectiveness in preventing COVID-19.
A new contrast agent has been developed to detect and image blood clots noninvasively, using a targeted approach to find clots anywhere in the body. The agent was tested in patients with atrial fibrillation and showed promising results.
Researchers found that blood flow simulation analysis can identify device-related thrombosis risks in left atrial appendage occluders. Personalized simulations before and after operation may improve patient outcomes.
The CAPTIVA trial will enroll 1,683 patients with symptomatic intracranial arterial stenosis and determine if two new prospective therapies are more effective than aspirin plus clopidogrel at reducing the risk of a second stroke. Intensive medical management and lifestyle modifications will also be provided to all patients.
The American College of Chest Physicians has released new clinical guidelines for venous thromboembolism (VTE) management, providing 29 recommendations on patient care and treatment. The guidelines update previous recommendations and offer strong guidance for clinicians managing patients with VTE.
A world-first study found that cancer patients receiving chemotherapy intravenously have more than double the risk of developing a blood clot or thrombosis if the vein is too small and the catheter occupies more than 45% of the vein. Researchers identified specific limits on catheter-to-vein ratios to reduce risks for cancer patients.
The FDA has approved Octagam 10% for treating adult dermatomyositis, a rare immune-mediated inflammatory disease. The approval is based on positive results of the ProDERM study, which showed significant improvement in patient response to treatment.
A recent study has made a breakthrough in understanding the process that leads to pulmonary embolism, a condition that kills over 2,000 people in the UK each year. Researchers have identified a protein called fibrin as crucial in stabilizing clots and preventing fragments from breaking loose.
Researchers have successfully treated a patient with vaccine-induced thrombotic thrombocytopenia (VITT) using intravenous immunoglobulin concentrates, cortisone, and specific anticoagulants. Prompt diagnosis and treatment can prevent life-threatening thrombosis.
Researchers found that apixaban reduced blood clot formation around implanted valves with no increased bleeding risk. However, a subset of patients showed higher rates of non-cardiovascular death without anticoagulation indication.
Research found that drinking flavanol-rich cocoa can improve blood vessel function during mental stress and reduce temporary impairments in endothelial function. Flavanols, commonly found in fruit and vegetables, have been shown to have a positive effect on cardiovascular health during periods of acute vascular vulnerability.
The FDA has approved supplements to biological license applications for Octaplas and fibryga, strengthening Octapharma USA's pediatric critical care product portfolio. The new labels provide results from post-marketing studies evaluating the products' efficacy, safety, and tolerability in newborns through age 20. Fibryga's indication i...
A new study by Christoph Binder's research group identifies IgM antibodies as a key player in preventing thrombosis. Natural IgM antibodies bind to microvesicles, preventing coagulation and thrombosis, providing a novel approach to reduce the risk of this major cause of death.
Researchers created potent trivalent inhibitors of thrombin from anticoagulation peptides in insect saliva, demonstrating improved efficiency over natural agents. The new agent showed 385-fold inhibition in human plasma and reduced fibrin accumulation, offering potential for efficient anticoagulation drugs.
Researchers will investigate genetic factors linking obesity and estrogen-containing birth control pills to stroke risk, aiming to identify drug targets for prevention or reduction.
Researchers analyzed five cases of patients with COVID-19 who experienced severe cardiac manifestations, including ST-elevated myocardial infarction (STEMI). NETs were found to form in coronary thrombuses, causing blockage of microvessels and contributing to the development of heart attacks.
RedHill's P2/3 COVID-19 candidate Opaganib has demonstrated reduced thrombosis in a preclinical model of ARDS. The study showed opaganib reduced blood clot length, weight, and total thrombus score in patients with severe respiratory distress syndrome induced by SARS-CoV-2.
A case of in-stent thrombosis (IST) occurred in an 81-year-old man undergoing coronary bypass grafting, highlighting the complexity of antiplatelet therapy choice and genetic testing in IST risk evaluation. The patient experienced IST after converting from ticagrelor to clopidogrel therapy.
Researchers identified a new prognostic laboratory sign for imminent postoperative thrombosis, which appears on the first postoperative day. Early detection using this sign can help prevent life-threatening thrombotic complications and improve patient outcomes.
Researchers found in situ pulmonary artery thrombosis associated with radiation therapy has unique imaging characteristics and does not typically embolize. The study identified 27 patients with PAT after RT, highlighting the importance of radiologist awareness for accurate diagnosis and management.
A systematic review found that hospitalized COVID-19 patients have a high risk of developing venous thromboembolism (VTE), with ICU patients at the highest risk. The study estimated that up to 28% of critically ill patients may develop deep vein thrombosis or pulmonary embolism.
Researchers aim to enroll patients aged 6-17 with moderate to severe PANS and evaluate the effectiveness of PANZYGA versus placebo in reducing symptoms. The study will also assess sustainability and functional impairment associated with PANS treatment.
Researchers at Uppsala University found that a key mechanism of clot formation in COVID-19 may be activation of the complement system, triggered by elevated mannose-binding lectin (MBL) levels and activity. MBL can contribute to a massive activation of the blood coagulation system, resulting in thrombosis.
A new analysis found that cerebral venous thrombosis (CVT) incidence has increased three times higher than previously reported in the US. CVT is most common in younger women, but recent findings suggest increases in men and older women, with a notable disparity in Black people compared to other racial and ethnic groups.
A patient with COVID-19 developed late drug-eluting stent thrombosis, a serious cardiovascular complication. The case report highlights the need for careful monitoring and management of patients with COVID-19 to prevent such adverse events.
Patients with high disease activity in rheumatoid arthritis are at a higher risk of developing venous thromboembolism. Treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) such as TNF inhibitors can reduce this risk by nearly half compared to conventional synthetic drugs.
A case series reports a high incidence of deep vein thrombosis among critically ill patients with COVID-19. The study highlights the need for prompt recognition and treatment of this potentially life-threatening complication in ICU patients with severe SARS-CoV-2 infection.
The FDA approved a phase 3 clinical trial to evaluate the efficacy and safety of high-dose Octagam 10% therapy in COVID-19 patients with severe disease progression. The study aims to determine if IVIG can slow or stop respiratory deterioration in these patients.
Researchers developed a miniature human vein device called Vein-Chip to study changes in vein wall cells and blood flow that lead to DVT. The technology allows for testing various factors such as gender and ethnicity to predict DVT risk, paving the way for personalized therapies.
A new study led by University of Kentucky researcher Sidney Whiteheart aims to understand how platelets function in hemostasis and during immune responses. The research may lead to therapies to regulate platelet activation and lessen the risk of cardiovascular disease in patients with HIV1/AIDS or COVID-19.
Recent reports show a strong association between elevated D-dimer levels and poor prognosis in patients with COVID-19. Microvascular thrombotic processes may play a role in respiratory failure, suggesting a new severe infectious lung disease with no proven therapies.